Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.57 |
| ▸ | PPARG | P37231 | 7/20 | 0.57 |
| ▸ | PPARD | Q03181 | 7/20 | 0.57 |
| ▸ | PPARA | Q07869 | 7/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | FABP4 | P15090 | 2/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2348686 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL15903953 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL2350916 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL2350035 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL561614 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL24538421 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL2348213 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL2989964 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL230198 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 | |
| SCHEMBL2346452 | 0.97 | TSHR (0.71) | LMNASLC15A2TSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120115014-A | Preparation method and application of MOF-based composite membrane | 山东理工大学 | 2025-06-10 | — | — | CN | claimed |
| US-20240166679-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION | 2024-05-23 | — | — | US | claimed |
| CN-117481384-A | Nicotine composition pouch and method of making same | 麦丰(珠海)科技有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-4301831-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG Corporation (US) | 2024-01-10 | — | — | EP | claimed |
| CN-117222726-A | Use of ketoacids for stabilizing lignin in lignocellulosic biomass extraction processes | 理革公司 | 2023-12-12 | — | — | CN | claimed |
| CN-113171693-B | Chemical sewage treatment method based on polysulfone composite microfiltration membrane | 中煤（北京）环保工程有限公司 | 2022-12-06 | — | — | CN | claimed |
| WO-2022187716-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION (US) | 2022-09-09 | — | — | WO | claimed |
| CN-114853795-A | Arylboron compound of conjugated olefin and preparation method and application thereof | 南京工业大学 | 2022-08-05 | — | — | CN | claimed |
| CN-113171693-A | Chemical sewage treatment method based on polysulfone composite microfiltration membrane | 河南鑫安利职业健康科技有限公司 | 2021-07-27 | — | — | CN | claimed |
| CN-105152903-B | Preparation method of aliphatic dicarboxylic acid | 中国科学院宁波材料技术与工程研究所 | 2021-03-16 | — | — | CN | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-6441198-B1 | USEFUL AS ANTITUMOUR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-08-27 | — | — | US | claimed |
| EP-0970039-B1 | METHOD OF OXIDIZING ALKYL-5-FORMYL VALERATE TO MONOALKYL ADIPATE | DU PONT (US) | 2001-11-14 | — | — | EP | claimed |
| EP-0970039-A1 | METHOD OF OXIDIZING ALKYL-5-FORMYL VALERATE TO MONOALKYL ADIPATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-01-12 | — | — | EP | claimed |
| US-5840959-A | NON-CATALYTIC AIR OXIDATION AT HIGH PRESSURE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-11-24 | — | — | US | claimed |
| WO-1998043939-A1 | METHOD OF OXIDIZING ALKYL-5-FORMYL VALERATE TO MONOALKYL ADIPATE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0569386-B1 | BRIDGED CYCLIC KETAL DERIVATIVES | GLAXO GROUP LTD (GB) | 1996-09-25 | — | — | EP | claimed |
| EP-0569386-A1 | BRIDGED CYCLIC KETAL DERIVATIVES. | GLAXO GROUP LTD (GB) | 1993-11-18 | — | — | EP | claimed |
| EP-0497091-A1 | Bridged cyclic ketal derivatives | GLAXO GROUP LIMITED (GB) | 1992-08-05 | — | — | EP | claimed |
| WO-1992012159-A1 | BRIDGED CYCLIC KETAL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-07-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166679-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | KHK, LCT, HOGA1 | LMNA 848/4885SLC15A2 3050/4885TSHR 4839/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | LMNA 2024/4885SLC15A2 3608/4885TSHR 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.